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Background: Medulloblastoma is a leading cause of childhood cancer-related deaths. Current aggressive
treatments frequently lead to cognitive and neurological disabilities in survivors. Novel targeted therapies are
required to improve outcome in high-risk medulloblastoma patients and quality of life of survivors. Targeting
enzymes controlling epigenetic alterations is a promising approach recently bolstered by the identification of
mutations in histone demethylating enzymes in medulloblastoma sequencing efforts. Hypomethylation of lysine 4
in histone 3 (H3K4) is also associated with a dismal prognosis for medulloblastoma patients. Functional
characterization of important epigenetic key regulators is urgently needed.
Results: We examined the role of the H3K4 modifying enzyme, KDM1A, in medulloblastoma, an enzyme also
associated with malignant progression in the closely related tumor, neuroblastoma. Re-analysis of gene expression
data and immunohistochemistry of tissue microarrays of human medulloblastomas showed strong KDM1A
overexpression in the majority of tumors throughout all molecular subgroups. Interestingly, KDM1A knockdown in
medulloblastoma cell lines not only induced apoptosis and suppressed proliferation, but also impaired migratory
capacity. Further analyses revealed bone morphogenetic protein 2 (BMP2) as a major KDM1A target gene. BMP2 is
known to be involved in development and differentiation of granule neuron precursor cells (GNCPs), one potential
cell of origin for medulloblastoma. Treating medulloblastoma cells with the specific KDM1A inhibitor, NCL-1,
significantly inhibited growth in vitro.
Conclusion: We provide the first evidence that a histone demethylase is functionally involved in the regulation of
the malignant phenotype of medulloblastoma cells, and lay a foundation for future evaluation of KDM1A-inihibiting
therapies in combating medulloblastoma.
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Medulloblastoma is the most common malignant brain
tumor of childhood [1]. Multimodal treatment regimens
have significantly improved survival rates of affected
children. However, more than one-third of patients
cannot be cured with conventional therapies, and the
aggressive treatments frequently lead to cognitive and* Correspondence: kristian.pajtler@uk-essen.de
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reproduction in any medium, provided the orneurological disabilities in survivors. Novel therapies are
required to improve both outcome in high-risk medullo-
blastoma patients and quality of life of survivors. New
therapeutic options are likely to result from a growing
understanding of the disease process, and will involve
small molecules targeting specific pathways that are
deregulated during oncogenesis [2]. Four tumor sub-
groups, termed WNT, SHH, group 3 (G3) and group 4
(G4), with distinct clinical, biological and genetic profiles
are now recognized [3]. WNT tumors, showing activated
wingless pathway signaling, carry a favorable prognosistd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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SHH tumors show hedgehog pathway activation, and
have an intermediate prognosis. G3 and G4 tumors are
molecularly less well characterized, and present the
greatest clinical challenges. Early phase results of small
molecule-based targeting of the sonic hedgehog pathway
in medulloblastoma patients have shown limited toxicity
and significant, although transient, clinical responses in
a refractory disease status of patients with activation of
hedgehog signaling in their tumors [4-6]. Clinical phase
II trials to further test efficacy are underway in young
adults with recurrent or refractory medulloblastoma that
have been stratified for hedgehog pathway activation in
the tumors. G3 and G4 tumors do not have many WNT
and SHH pathway aberrations, so another avenue of
targeting may still be necessary to effectively treat these
tumors.
Particularly for G3 and G4 medulloblastomas, atten-
tion is increasingly drawn towards considering deregu-
lating enzymes involved in epigenetic gene regulation
based on mounting molecular evidence. Histone
acetylases and histone methylases have been shown to
specifically regulate central genes in these medulloblas-
tomas [7-9]. Recent sequencing efforts describing the
mutational landscape of medulloblastoma have identified
mutations in histone demethylating enzymes predomin-
antly in G3 and G4 tumors [10]. A recent immunohisto-
chemical analysis also demonstrated alterations of the
histone code in 24% (53/220) of medulloblastomas
across all subgroups [11]. The clinical and biological sig-
nificance of these mutations and histone code changes
remain as yet primarily uncharacterized. Since histone-
modifying enzymes are promising drug targets modulat-
ing broad expression patterns of cancer-associated
genes, the functional characterization of these important
key players and their role in specific cancers is urgently
needed.
In the past, histone methylation was considered to be
static and irreversible. However, a new class of histone
demethylating enzymes was identified several years ago,
with the lysine (K)-specific histone demethylase 1A
(KDM1A, originally referred to as LSD-1) as its proto-
type [12]. KDM1A specifically interacts with the androgen
receptor or with large chromatin-modifying corepressor
complexes such as the Co-REST complex, suggesting that
high-level KDM1A expression might already affect genes
during the embryonal development of potential cancer
progenitor cells [13-15]. Specifically, demethylation of
lysine residues 4 or 9 of histone 3 by KDM1A can initiate
or repress, respectively, transcription driven by transcrip-
tion factors or corepressor complexes [12,13]. In the re-
cent paper by Dubuc et al., particularly G3 and G4
medulloblastomas with dismal outcomes were character-
ized by demethylation of H3K4 and H3K27, leading theauthors to suggest histone modifying therapies as a prom-
ising approach for a subset of medulloblastoma patients
[11]. PRC2-mediated aberrant methylation of H3K27 has
previously been targeted for therapy in medulloblastoma
and lymphoma [16,17]. We have recently demonstrated
involvement of KDM1A and H3K4 demethylation in the
malignant progression of neuroblastoma, a challenging
embryonal pediatric cancer sharing many morphological
and molecular features with medulloblastoma [18]. High-
level KDM1A expression in neuroblastomas is associated
with an aggressive clinical course, and pharmacological
inhibition of KDM1A significantly reduced growth of
human neuroblastoma cell lines grown as xenografts in
nude mice. Early relapsed prostate carcinomas, sarcomas,
and specific types of breast cancer also exhibit high-level
KDM1A expression [13,19-21]. These data identify
KDM1A as a promising therapeutic target for a variety of
tumors and warrant its evaluation in medulloblastoma.
Based on the very recent observations that (1) several
mutations occur in histone demethylation pathways in
medulloblastomas, (2) aberrant H3K4 methylation is
associated with dismal prognosis in a subset of medullo-
blastoma patients and (3) KDM1A is a promising H3K4
modifying epigenetic target in several cancers, including
other embryonal tumors, which controls broad expres-
sion programs during cellular development and malig-
nant progression, we hypothesized that KDM1A might
also be an important functional player in medulloblas-
toma. Similar to inhibition of aberrant methylation of
H3K27, inhibition of KDM1A-mediated demethylation
of H3K4 might then be a promising innovative targeted
therapy approach. In this study, we analyzed KDM1A
expression in primary human medulloblastomas and
murine medulloblastic tumors. We further used cell
models for medulloblastoma to assess the role of
KDM1A in processes associated with malignancy,
including the regulation of cell proliferation, death and
motility. Finally, we tested the efficacy of a novel small
molecule inhibitor of KDM1A in cell models for
medulloblastoma.
Results
KDM1A is overexpressed in human medulloblastomas,
cell lines derived from them and murine medulloblastic
tumors
As a first step to analyze the role of KDM1A in medullo-
blastoma, we assessed KDM1A expression in 62 primary
human medulloblastomas. Re-analysis of publicly available
microarray data revealed a highly significant upregulation
of KDM1A mRNA in primary medulloblastomas com-
pared to normal human cerebellum (Figure 1a) [22,23].
Interestingly, re-analysis of KDM1A expression in distinct
medulloblastoma subtypes did not reveal significant differ-
ences between KDM1A expression levels in the subgroups
Figure 1 KDM1A is strongly overexpressed in human medulloblastomas, cell lines derived from them and murine medulloblastic
tumors. a Data from a representative cohort of 62 medulloblastomas (MB) and normal cerebellar tissue (CB) used in a published microarray
analysis [22,23] were re-analyzed for KDM1A expression. ***p < 0.0001 b KDM1A protein expresion was evaluated immunohistochemically in a
tissue microarray of 70 medulloblastomas (MB) and 9 tissue samples of normal cerebellum (CB). Micrograph showing KDM1A-positive staining in
a representative MB sample, and KDM1A-negative staining in CB, scale bar = 100 μm. c Bars reflect the proportion of cells with strong (black),
moderate (dark grey), weak (light grey) or no (white) nuclear KDM1A staining. A two-tailed student’s t-test revealed a significant upregulation of
KDM1A protein in the medulloblastomas represented in the tissue microarrays. ***p < 0.0001 d Bars represent KDM1A expression measured using
real-time RT-PCR and normalized to the geometric mean of GAPDH, UBC and HPRT expression in a panel of human medulloblastoma cell lines
derived from diverse histological tumor subtypes and the SK-N-BE human neuroblastoma cell line, known to express high levels of KDM1A as a
reference. e Bars represent KDM1A expression measured using real-time RT-PCR in medulloblastic tumors (black) spontaneously arising in
genetically engineered mice with activating mutations in the sonic hedgehog pathway, SmoA1 MB (p = 0.014) and Ptch+/− MB (p = 0.037),
compared to normal murine cerebellum (CB, white). f Strong KDM1A protein expression was confirmed in the medulloblastic tumors from
SmoA1- and Ptch+/−-mice relative to KDM1A expression in cerebellar tissue (CB) using western blotting of tissue lysates. β-actin expression was
used as a loading control.
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expression in medulloblastomas, a tissue microarray was
prepared incorporating 70 primary human medulloblasto-
mas prior to treatment and 9 samples of unaltered normal
cerebellar tissue as controls. KDM1A protein levels were
semiquantitatively assessed after immunohistochemical
staining of the TMA. KDM1A expression was restricted
to the nuclei of tumor cells, with 90% of tumor cells stain-
ing positively for KDM1A (10 samples (14.3%) exhibitedweak staining, 22 samples (31.4%) exhibited moderate
staining and 31 samples (44.3%) exhibited strong staining;
Figure 1b-c). KDM1A was not expressed in the normal
cerebellar tissue or in nonmalignant cells in the tumor
samples, such as stromal tissue. We next investigated
KDM1A expression in a panel of cell lines derived from
medulloblastomas using real-time RT-PCR. All cell lines
strongly expressed KDM1A, and the expression level
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Figure 2 KDM1A inhibition impairs cell proliferation and migration and induces apoptosis in human medulloblastoma cell lines. a Bars
represent KDM1A expression measured using real-time RT-PCR and normalized to the geometric mean of GAPDH, UBC and HPRT expression in
DAOY and ONS-76 cell lines 72 h after KDM1A knockdown or mock transfection. ***p < 0.0001 b Knockdown of KDM1A protein was confirmed
by western blotting of whole-cell lysates from DAOY and ONS-76 cells. β-actin served as loading control. c The DAOY and ONS-76
medulloblastoma cell lines were transfected with siRNA directed against KDMA1, and cell viability was measured using the MTT assay. Extinction
relative to mock-transfected cultures at 72 h is shown. ***p < 0.0001 d Proliferation of DAOY and ONS-76 cells following mock transfection or
transfection with siRNA directed against KDM1A was assessed by BrdU ELISA. Bars show extinction relative to mock-transfected cultures at 72 h.
***p < 0.0001 e Apoptosis in DAOY and ONS-76 cells was measured by Cell Death Detection ELISA™ 72 h after transfection with either siRNA
directed against KDMA1 or mock transfection. Extinction is relative to mock-transfected cultures. ***p < 0.0001, *p < 0.05 f Migratory activity was
assessed for the ONS-76 cell line 48 h after transfection with either siRNA directed against KDM1A or mock transfection in Boyden chamber
assays. Representative images of DAPI-stained mock-transfected control cells (ONS-76 ctrl) and KDM1A-knockdown cells (ONS-76 siKDM1A)
invading the membrane (scale bars = 100 μm). g Statistical analysis of results from Boyden chamber assays 24 h after DAOY and ONS-76 cells,
either transfected with siRNA directed against KDM1A or mock-transfected, were plated in the upper chamber. Bars display quantity of cells per
mm square which migrated through the membrane. **p < 0.01, *p < 0.05.
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high levels of KDM1A (Figure 1d) [18].
To assess whether overexpression of the KDM1A
enzyme is a conserved event in medulloblastic tumors
across species, we analyzed KDM1A expression in two
transgenic mouse models for medulloblastic tumors.
Activating mutations have been introduced in the sonic
hedgehog pathway in SmoA1 and Ptch+/− mice, and
these mice are frequently used as in vivo model systems
to study medulloblastoma development and therapy.
Both mouse models develop medulloblastic tumors
spontaneously between 2 and 10 months of life. We
assessed KDM1A expression in murine medulloblastic
tumors on both mRNA and protein level. KDM1A
mRNA levels were significantly higher in medulloblastic
tumors from SmoA1- and ptch+/−-mice than in normal
cerebellar tissue from mice with the same genetic back-
ground (Figure 1e), as was KDM1A protein expression
in these murine medulloblastic tumors (Figure 1f ).
Taken together, these data show extensive KDM1A de-
regulation in primary human medulloblastoma, cell lines
derived from them and murine medulloblastic tumors,
suggesting a crucial role for KDM1A in medulloblastic
tumors across species.
KDM1A inhibition impairs cell proliferation and migration
and induces apoptosis in human medulloblastoma cell
lines
We next examined whether KDM1A knockdown had a
notable impact on tumorigenic characteristics in medul-
loblastoma cells. The DAOY and ONS-76 medulloblas-
toma cell lines were transiently transfected with siRNA
directed against KDM1A or with transfection agent
alone. A significant knockdown of KDM1A was detected
on both the mRNA (Figure 2a) and protein (Figure 2b)
levels 48 h after transfection. KDM1A knockdown sig-
nificantly reduced cell viability in MTT assays conducted
72 h after transfection (Figure 2c). Cell proliferation was
also assessed using BrdU incorporation 72 h after trans-
fection. A strong reduction in the number of proliferat-
ing cells was observed that corresponded well to the
observed reduction in cell viability after KDM1A knock-
down (Figure 2d). Since it is critical for therapy success
that the treatment kills tumor cells, and not just arrests
them during the cell cycle, we next assessed whether
KDM1A knockdown induced apoptosis in medulloblas-
toma cells. The Cell Death Detection ELISA™ confirmed
that observed phenotypic changes were predominantly
due to apoptotic induction (Figure 2e). These experi-
ments show that KDM1A knockdown impaired medul-
loblastoma cell viability and proliferation and induced
apoptosis.
Huang and colleagues reported that demethylation
activity by KDM1A maintains TP53 in an inactive state,thus, preventing DNA binding and supporting tumori-
genesis [24]. Previously, we identified TP53 mutations in
DAOY cells, which lead to TP53 dysfunction indicated
by low CDKN1A (previously known as p21) expression
[25]. The ONS-76 medulloblastoma cell line harbors the
R72P SNP in TP53, but TP53 function and expression
are normal in these cells. Since KDM1A knockdown in
DAOY and ONS-76 cells resulted in similar levels of
proliferative suppression and apoptotic induction, one
could speculate that TP53 function was not involved in
effects mediated by KDM1A inhibition in medulloblas-
toma cells. However, this hypothesis would need to be
validated in further experiments.
Migratory capacity of tumor cells is another hallmark of
cancer that is particularly important in brain tumor patho-
genesis. To investigate whether KDM1A can also influ-
ence migratory capacity in medulloblastoma cells, we used
Boyden chamber assays to assess migratory capacity after
KDM1A knockdown. KDM1A knockdown effectively di-
minished the strong migratory capacity of both DAOY
and ONS-76 medulloblastoma cells (Figure 2f and 2g).
Taken together, our data from cellular models for medul-
loblastoma show that KDM1A influences three major
hallmarks of cancer cells, uncontrolled cell proliferation,
avoidance of apoptosis and migratory capacity. Our results
also support that effects of KDM1A on cell viability and
apoptosis could be independent of effects mediated by
TP53, but cannot conclusively rule out an interaction
between KDM1A and TP53.
Bone morphogenetic protein 2 (BMP2) is a potential
KDM1A target gene
Since our data indicated that KDM1A is highly relevant
for critical biological characteristics of medulloblastoma,
we next aimed to identify important target genes of
KDM1A. Gene expression was analyzed in ONS-76 cells
using Affymetrix microarrays 72 h following transfection
of either siRNA directed against KDM1A or transfection
reagent alone. KDM1A knockdown resulted in a >3-fold
induction of 30 genes and a >3-fold repression of 4
genes in ONS-76 cells (Figure 3a and Additional file 1:
Table S1). Interestingly, comparing previously published
expression data following KDM1A knockdown in neuro-
blastoma cells with expression data following KDM1A
knockdown from this study suggested that KDM1A
effects are specific for the tumor entity [18]. None of the
strongly induced or repressed genes (significantly in-
duced or repressed by at least 3-fold) in neuroblastoma
and medulloblastoma cells were similarly regulated in
cells derived from both tumor entities. Among the 30
genes induced in response to KDM1A knockdown, the
enhancement of BMP2 expression was particularly strik-
ing. The increase in BMP2 expression had the highest






























Figure 3 Bone morphogenetic protein 2 (BMP2) is a potential KDM1A target gene. a Heatmap shows unsupervised clustering of gene
expression obtained for the ONS-76 medulloblastoma cell line 72 h after KDM1A knockdown (right) or mock transfection (left) using Affymetrix
U133 Plus 2.0 microarrays. Upregulated genes are represented in red and downregulated genes are represented in blue. KDM1A knockdown was
verified in the microarray expression analysis (black arrow), and BMP2 was significantly induced (red arrows, p = 6.4 × 10-6 and 5.4 × 10-5 for the
two BMP2 HGU133_Plus Affymetrix array probe sets for BMP2, 205289_at and 205290_s_at, respectively). b The significant increase of BMP2
expression upon KDM1A knockdown was confirmed by real-time RT-PCR for ONS-76 cells 72 h after knockdown or mock transfection. *p < 0.05
c KDM1A knockdown increased the level of phosphorylated SMAD5 by 220% detected in western blots of whole-cell lysates of ONS-76 cells 72 h
after knockdown or mock transfection. β-actin expression was used as a loading control.
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tumorigenic potential of human brain tumor-initiating cells
[26]. BMP2 has also been previously shown to be involved
in the normal development and differentiation of GNPCs,
the cells of potential origin of SHH medulloblastomasubtypes [27,28]. We confirmed upregulation of BMP2 ex-
pression in response to KDM1A knockdown in an inde-
pendent experimental setting using real-time RT-PCR
(Figure 3b and Additional file 1: Figure S3). To assess
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Figure 4 Inhibiting KDM1A using small molecules,
tranylcypromine or NCL-1, effectively suppressed
medulloblastoma cell growth in vitro. a The DAOY and ONS-76
medulloblastoma cell lines were treated with the indicated
concentrations of the monoaminoxidase inhibitor, tranylcypromine,
and cell viability was measured by the MTT assay. Extinction relative
to solvent-treated cultures at 72 h is shown for the mean of 4
experiments conducted in triplicate. b The medulloblastoma cell
lines, DAOY and ONS-76 were treated 72 h with 10 μM of the
KDM1A-selective inhibitor, NCL-1, or with solvent, then cell viability
was measured in MTT assays. Bars represent the means of 3
independent experiments conducted in triplicate. ***p < 0.0001.
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phorylation of a downstream signaling element in the
BMP2 pathway, SMAD5. In ONS-76 cells, transfected with
siRNA targeting KDM1A or transfection reagent alone,
KDM1A knockdown increased the proportion of phos-
phorylated SMAD5 protein by 220% (Figure 3c). These
data show that BMP2, which is involved in brain tumor
suppression and the regulation of proliferative
responses of a distinct medulloblastoma precursor cell
type, is downregulated in ONS-76 cells. Furthermore,
KDM1A knockdown not only upregulated BMP2, but
increased BMP2 activity, as indicated by phosphoryl-
ation of the signaling intermediary, SMAD5.
Small molecule inhibitors of KDM1A effectively inhibit
medulloblastoma growth in vitro
The amino acid sequence of the KDM1A catalytic domain
has homology to monoaminoxidase (MAO), and uses the
same demethylating mechanism. Monoaminoxidase inhib-
itors (MAOIs) have been demonstrated to have inhibitory
activity on KDM1A, and were introduced as the first avail-
able small molecular inhibitors of KDM1A for this reason
[29]. We have previously reported that MAOI treatment
can significantly affect neuroblastoma cell proliferation
in vitro and in vivo [18]. Tranylcypromine impaired
growth of medulloblastoma cell lines DAOY and ONS-76
in a dose-dependent manner, with IC50 values of
0.38 mM and 1.76 mM, respectively (Figure 4a). Since
high MAOI doses are required to also inhibit KDM1A,
these drugs have severe side effects when used in these
doses in mice [18]. Therapeutic inhibition of KDM1A will,
therefore, require specific inhibitors of KDM1A. NCL-1 is
a small molecule developed by Ueda and colleagues,
which was reported to specifically inhibit KDM1A, but
not type A and B MAOs [30,31]. We treated the DAOY
and ONS-76 medulloblastoma cell lines with 10 μM
NCL-1, a concentration which was previously reported to
impair proliferation of KDMA1-expressing glioblastoma
cells [32]. After 72 h of treatment, cell viability was
reduced by 63% in DAOY cells and 54% for ONS-76 cells
compared to the respective untreated controls (Figure 4b).
These data demonstrate that targeting KDM1A specific-
ally using small molecule inhibitors in medulloblastoma
cells, which express high levels of KDM1A, can signifi-
cantly impair tumor cell viability. In fact, NCL-1 had a
comparable effect on DAOY and ONS-76 cells in vitro to
KDM1A knockdown.
Discussion
Here we provide the first evidence that KDM1A plays a
functional role in maintaining tumorigenic properties in
medulloblasoma. Medulloblastomas, cell lines derived
from medulloblastomas and meduloblastic tumors from
genetically engineered mouse models for medulloblastomaexhibit high-level KDM1A expression in comparison to
normal cerebellar tissue. KDM1A inhibition can effect-
ively antagonize important hallmarks of medulloblastoma
progression including proliferation, resistance to apoptosis
and migration. BMP2 signaling via SMAD5 is a potentially
important downstream effector of KDM1A functionality.
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small molecule inhibitor, presents a promising new strat-
egy to treat medulloblastoma, which should be clinically
evaluated.
Chromatin modifiers influencing gene expression by
histone acetylation or methylation are emerging as an
interesting new approach to target cancers. Recently,
several next-generation tumor sequencing projects have
identified frequent mutations in chromatin remodeling
genes in a variety of entities, including medulloblastoma,
supporting the hypothesis that these modifiers might
contribute to the malignant progression of cancer [33,34].
We and others previously reported that overexpression of
KDM1A in several tumor entities correlates strongly with
tumor aggressiveness, adverse outcome, and cellular dedif-
ferentiation [15,18,19,32]. This is in line with our findings
in the current study, showing that approximately 90% of
primary human medulloblastomas that predominantly
consist of cells with undifferentiated appearance, were
shown to be KDM1A positive [35]. Remarkably, we found
similar alterations of KDM1A expression across the
species barrier in genetically engineered mouse models for
medulloblastoma, increasing the probability that KDM1A
plays a critical role in medulloblastoma initiation and/or
progression and making it a top candidate for further val-
idation [36]. Since KDM1A overexpression was detected
in all molecular subgroups of human medulloblastomas,
transgenic mice with activating mutations in the sonic
hedgehog pathway are likely to be suitable mouse models
to preclinically test KDM1A inhibitors, even though these
models mimic major genetic alterations that occur in only
approximately 25% of medulloblastomas [37].
We show here that BMP2 was upregulated in medullo-
blastoma cell lines following KDM1A knockdown. In
line with our results, Adamo and colleagues reported a
strong correlation between KDM1A knockdown and
induction of BMP2 expression in undifferentiated
embryonic cells [38]. BMP2 induces apoptosis in mye-
loma cells and, remarkably, it was previously shown by
Hallahan and colleagues that both, recombinant BMP2
treatment and enforced BMP2 expression following
retinoid treatment, can induce apoptosis in medulloblas-
toma cells [39,40]. However, in their study BMP2-
mediated apoptosis was restricted to cells responsive to
retinoids, thus, excluding this mechanism of action in a
variety of medulloblastoma-derived cell lines, including
DAOY. Based on our data demonstrating that apoptosis
is induced even in DAOY cells following KDM1A knock-
down, we suggest that KDM1A inhibition can circum-
vent the blockade of BMP2-mediated apoptosis in
medulloblastoma cells incapable of responding to reti-
noids. The molecular mechanism of the interaction
between KDM1A with BMP2 signaling requires further
experiments for elucidation, but these data implicatethat some functionality of high-level KDM1A expression
may be mediated by downregulating BMP2 signaling.
BMP2 activation contributes to cell cycle arrest, apop-
tosis or differentiation of GNPCs, which are considered
to be the cells of origin for SHH driven medulloblasto-
mas [27,28,41,42]. BMP2 signaling is initiated by phos-
phorylation of SMAD5, and activates KLF10 resulting in
MYCN inhibition or posttranscriptionally downregulates
ATOH-1 via ID1/2 induction [28,41]. BMP2 is expressed
weakly in medulloblastoma throughout all molecular
subgroups, but lowest levels are detected in tumors
assigned to the SHH group (reanalysis of data from
Northcott et al. [43], Additional file 1: Figure S1a and b).
Thus, by downregulating BMP2, SHH group medullo-
blastomas might escape from apoptotic signals or main-
tain an undifferentiated phenotype. However, the most
commonly used medulloblastoma-derived cell lines,
which we also used here, are not depending on constitu-
tive activation of sonic hedgehog signaling and KDM1A
knockdown did not result in any significant change of
expression in genes belonging to the sonic hedgehog
signaling pathway (Additional file 1: Table S2) [44,45]. We
suggest that BMP2 upregulation in response to KDM1A
knockdown could be an intermediate to inducing apop-
tosis in medulloblastoma cells, but acting via routes differ-
ent from sonic hedgehog pathway inhibition.
Medulloblastoma has a strong tendency to metastasize
and metastatic disease is still the most important factor
in risk stratification [46,47]. An indispensable require-
ment for malignant cells to invade and spread is their
ability to develop migratory capacity. Here, we show that
the migratory activity of medulloblastoma cells was sig-
nificantly reduced by KDM1A knockdown. Interestingly,
gene ontology analysis of microarray expression data
revealed a significant down-regulation of genes involved
in cell migration and motility following KDM1A knock-
down (Additional file 1: Table S3). A study recently pub-
lished by Serce and colleagues supports our results by
showing that KDM1A expression gradually increases
during tumor progression from pre-invasive neoplasia to
fully invasive disease in ductal carcinoma of the breast
[48]. Ferrari-Amorotti and colleagues found that
KDM1A influences the motility and invasiveness of
neuroblastoma and colon carcinoma cells [49]. Through
interaction with Slug, which is a member of the E-box–
binding family of transcriptional repressors, KDM1A
represses expression of epithelial and induces expression
of mesenchymal markers. Via this mechanism, KDM1A
supports the process of epithelial–mesenchymal transi-
tion (EMT), which might also be involved in cell inva-
sion of nonepithelial cancers including glioblastoma
[50]. Remarkably, EMT was also previously described to
increase invasiveness of DAOY and other medulloblas-
toma cell lines [51]. Taken together, these findings
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ness of cancer cells of various origins including medullo-
blastoma, which might be based on induction of
mesenchymal cellular properties.
Although Huang et al. suggested that KDM1A-
mediated demethylation affects TP53 function, we did
not observe different effects of KDM1A inhibition in
medulloblastoma cells with functional or dysfunctional
TP53. Jin and colleagues demonstrated that TP53 func-
tion is not affected in cells with homozygous KDM1A
knockout (KDM1A−/−), while both mRNA and protein
expression of the TP53 target gene, CDKN1A, are sig-
nificantly elevated compared to cells with heterozygous
KDM1A knockout or the cell line from which they are
derived [52]. This might be explained by KDM1A-
mediated demethylation of the CDKN1A promoter at
H3K9, which would provide transcription factors bind-
ing GC-rich regions better access to the DNA, thus,
bypassing TP53 [53]. However, here we did not observe
significant changes in CDKN1A expression after 72 h of
KDM1A knockdown (Additional file 1: Table S2). This
may have been a result of the partial silencing of
KDM1A via knockdown, making these cells more similar
to the situation in the cells with heterozygous KDM1A
knockout. Although the precise molecular mechanisms
involved are not yet clear, our results support the rea-
soning that expression of KDM1A in medulloblastomas
might perpetuate cell proliferation, at least in part, by a
TP53-independent manner, implying that therapeutically
targeting KDM1A could also be efficient against medul-
loblastomas harboring TP53 mutations.
Although MAOIs are very effective in vitro, and they
did significantly suppress the growth of neuroblastoma
xenograft tumors in mice, their lack of specificity for
KDM1A requires treatment with high doses, which
cause extensive side effects in whole animal testing
models [18]. For these reasons, it is unlikely that MAOIs
will be able to make the transition to the clinic as cancer
therapeutics. However, preclinical in vitro testing of the
highly specific small molecule inhibitor, NCL-1 in
aggressive gliomas, are very promising [32]. It has been
broadly experienced that targeting hallmarks of cancer
cells by inhibiting angiogenesis, blocking antiapoptotic
proteins or inhibiting tumor-associated receptor tyrosine
kinases that provide survival signals is most often
circumvented by resistance mechanisms in malignant
cells during tumor progression. The problem of resist-
ance to targeted therapies certainly needs to be
addressed by developing multimodal strategies using
intelligent combinations of targeted therapies [54,55]. As
reprogramming of medulloblastoma cells appears to be
possible by interfering with enzymes manipulating epi-
genetic patterns, a combination of histone demethylase
and deacetylase (HDACs) inhibitors might prove usefulto prevent the development of resistance to treatment
and achieve a maximal effect. Notably, inhibition of
KDM1A and HDAC turned out to have synergistic
effects inhibiting tumor development in other types of
brain tumors [56-58]. In respect to potential side effects
of a specific systemic pharmacological KDM1A inhib-
ition, which need to be taken into consideration for clin-
ical trial planning, we have recently shown a significant
but transient suppression of hematopoetic cells in the
bone marrow in a conditional LSD1 knockout mouse
model [59]. The fundamental role of KDM1A in prostate
and breast cancer will presumably support a rapid
realization of clinical phase I/II studies with KDM1A
inhibitors in adults, which will in turn open new avenues
for treatment of pediatric embryonal tumors, including
medulloblastomas.
Conclusion
In this study we provide the first evidence that the
histone demethylase KDM1A is functionally involved in
the regulation of the malignant phenotype of medullo-
blastoma cells by influencing three major hallmarks of
cancer cells, uncontrolled cell proliferation, avoidance of
apoptosis and migratory capacity. Treatment of medullo-
blastoma cells with a novel specific KDM1A inhibitor,
the small molecule NCL-1, led to significant inhibition
of cellular growth in vitro. In conclusion, data resulting
from our work lay a first preclinical foundation for
future evaluation of KDM1A-inhibiting therapeutic ap-
proaches against medulloblastoma including transgenic
and xenograft mouse models.
Methods
Immunohistochemistry and tissue microarrays
Tissue microarrays (TMAs) were prepared from
paraffin-embedded tissue specimens from 70 primary
medulloblastomas and 9 cerebellum samples as previ-
ously described [25]. Three different tissue cores within
a single tumor were arrayed from formalin-fixed,
paraffin-embedded tissue blocks using a manual device
(Beecher Instruments, Sun Prairie, WI, USA). Two
micrometer paraffin sections were cut from every tissue
microarray and used for subsequent immunohistochemical
analyses. Immunohistochemical staining was conducted as
previously described [19]. In brief, formalin-fixed paraffin-
embedded tissue sections were deparaffinized by routine
techniques, and placed in 200 ml of target retrieval solu-
tion, pH 6.0 (Envision Plus Detection Kit, Dako, Glostrup,
Denmark) for 20 min at 100°C. After cooling 20 min,
slides were quenched with 3% H2O2 for 5 min before incu-
bating with primary antibody in a Dako Autostainer
(Dako Cytomation, Glostrup, Denmark). The primary
antibody against KDM1A was diluted 1:250 (Cat.#
NB100-1762, Novus Biologicals, Littleton, CO, USA).
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uated using a semiquantitative scoring system. In a first
step, the number of positive cells was counted and
scored (0 = no positive nuclei, 1 = <10% of nuclei are
stained, 2 = 10-50% of nuclei are stained, 3 = 51-80% of
nuclei are stained and 4 = >80% of nuclei are stained).
In a second step, the staining intensity in positive cells
was assessed and scored (0 = no positive nuclei, 1 = weak
staining, 2 =moderate staining and 3 = strong staining).
The total score for the overall KDM1A protein expression
level (0–3 = negative, 3–6 = weak, 6–9 = moderate and
9–12 = strong) was calculated by multiplying the two
scores. Unfortunately, tumor subgroup information was
not available for the tumors arrayed on this TMA. Thus,
the correlation between tumor subgroup and KDM1A
expression could not be assessed. Written informed con-
sent was obtained from the patients within the respective
clinical study for publication of reported data and accom-
panying images.
Real-time RT-PCR
Total RNA was isolated from cells using the RNeasyMini
kit (Qiagen, Hilden, Germany), and cDNA synthesis was
performed using the SuperScript reverse transcription
kit (Invitrogen, Darmstadt, Germany). KDM1A and
BMP2 expression was monitored by real-time PCR using
“Assays on Demand” (Applied Biosystems, Carlsbad,
CA, USA). Expression values were normalized to the
geometric mean of GAPDH, UBC and HPRT expression
[60]. Data were analyzed using qBase 1.4 (Biogazelle,
Ghent, Belgium).
Western blotting
Protein lysates were extracted from cells and blotted as de-
scribed in Kahl and colleagues [19]. The membranes were
incubated for 1 to 2 h with either antibodies recognizing
KDM1A (Cat.# NB100-1762, Novus Biologicals, Littleton,
CO) diluted 1:1,000, SMAD1/5 phosphorylated on Ser463/
465 (Cat.# 9516, Cell Signaling, Danvers, MA, USA)
diluted 1:1,000 or β-actin (Sigma-Aldrich, Taufkirchen,
Germany) diluted 1:5,000. ImageJ 1.42q (W. Rasband,
NIH, Bethesda) was used to measure signal intensities.
Cell culture and siRNA transfection
The DAOY and ONS-76 human medulloblastoma cell
lines were cultivated in RPMI 1640 supplemented with
10% FCS, L-glutamine and antibiotics. For siRNA trans-
fection, 1 × 103 or 1 × 104 cells were seeded onto 96- or
12-well plates, respectively, then incubated for 24 h in
standard medium in the presence of 10nM siRNA
directed against KDM1A (DNA target sequence, 5-
AACACAAGGAAAGCTAGAAGA-3) complexed with
HiPerFect Transfection Reagent (Qiagen) or with vehicle
according to the manufacturer’s instructions.Cell viability, proliferation, and death analysis
Cells were seeded onto 96-well plates (1 × 103 per well)
in triplicate, incubated for 6 h to permit surface adher-
ence, then treated with 0 to 5 mM tranylcypromine
(Biomol, Hamburg, Germany), 10 μM NCL-1, or 10nM
siRNA directed against KDM1A. Medium was replaced
daily, and tranylcypromine and NCL-1 concentrations
were constant throughout the experiment. Cell viability
was analyzed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay (Roche,
Mannheim, Germany), according to the manufacturer’s
protocol. Apoptosis was assessed using the Cell Death
ELISA (Roche), cell proliferation was assayed using the
BrdU ELISA (Roche), and both were performed 72 h
following siRNA transfection according to the manufac-
turer’s protocols. All experiments were independently
performed in triplicates at least three times, if not other-
wise indicated.
Boyden chamber assay
Assays were performed using 12-well Boyden chambers
containing HTS FluoroBlok™ 8.0 μm colored PET mem-
brane inserts (BD, Franklin Lakes, NY, USA). DAOY or
ONS-76 cells (2.5 × 103) were seeded in triplicate into
the upper chamber compartments containing 250 μl cell
culture medium with 0.5% FCS 48 h after transfection
with siRNA directed against KDM1A. The lower com-
partment was filled with 800 μl cell culture medium
containing 10% FCS. After 24 h membranes were
exposed for 30 seconds to 4',6-diamidino-2-phenylindole
(DAPI, Invitrogen). Cells on the lower surface of the
membrane were counted using fluorescence microscopy
as described previously [61]. Experiments were carried
out in triplicate, and were repeated three times.
Microarray analysis
RNA was isolated from ONS-76 cells transfected with
siRNA directed against KDM1A or treated with vehicle
from three independent transfection experiments each
(3 chips vs 3 chips). Reverse transcription, labeling of
total RNA, and subsequent hybridization to Affymetrix
U133v2 chips were performed according to the manu-
facturer’s protocols and as previously described [62].
Only genes with a three-fold change in gene expression
after statistical analysis were considered for further ana-
lysis. Gene ontology analysis was performed according
to [63]. Microarray data have been deposited in the GEO
database, accession no. GSE43552.
Murine tumor material
Ptch+/− [64] or SmoA1 mice [65] were sacrificed after
tumors developed in the posterior fossa and neurological
symptoms appeared. Tumors were extracted and tumor
material was mechanically dissociated. Total RNA was
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(Qiagen) for real-time RT-PCR. For western blotting,
dissociated tumor material was extracted in RIPA buffer
(Sigma-Aldrich) to lyse cells and solubilize proteins. All
experiments were performed in accordance with the
principles of laboratory animal care (NIH publication
NO. 86–23, revised 1985) and German laws for animal
protection.
Statistics
Data normalization of microarray experiments were
performed using the robust multi-array average (RMA)
algorithm included in the Partek Genomics Suite soft-
ware (Partek, MO, USA). An ANOVA 1-way was
performed to test for differentially expressed genes
between KDM1 knockdown and mock-transfected cells.
Microarray expression profiles previously obtained by
Kool and colleagues from 62 primary medulloblastomas
were reanalyzed to assess KDM1A expression levels in
tumor and control tissues [22]. Unfortunately, the
corresponding survival data for the patients from which
these tumors were removed were unavailable. Thus, the
prognostic value of KDM1A expression in the tumor
could not be assessed for medulloblastoma patients.
Data analyses were performed using the R2 platform
(http://r2.amc.nl). Written informed consent was obtained
from the patients within the respective clinical study for
publication of reported data. SPSS 18.0 (IBM, Ehningen,
Germany) was used to conduct student’s two-sided t-tests
to compare all interval variables and chi-square tests to
compare all categorical variables. All error bars relate to
the mean +/− SD, if not otherwise indicated. Graph Pad
Prism 5.0 (San Diego, CA, USA) was used to calculate
IC50 concentrations.
Availability of supporting data
The microarray data supporting the results of this article
are available in the GEO database, accession no.
GSE43552 in http://www.ncbi.nlm.nih.gov/geo/.
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Additional file 1: Table S1. Genes significantly induced or repressed in
the ONS-76 cell line by at least 3-fold 72 h after KDM1A knockdown from
expression analysis conducted on Affymetrix Microarray GeneChip
Human Genome U133 Plus 2.0. Table S2. Normalized expression of
genes involved in sonic hedgehog signaling and of TP53 and p21/
CDKN1A 72 h following KDM1A knockdown in ONS-76 cells. Table S3.
GO analysis on all significantly regulated genes 72 h following KDM1A
knockdown in ONS-76 cells. Figure S1. BMP2 expression in primary
medulloblastomas. Figure S2. KDM1A expression in subgroups of primary
medulloblastomas. Figure S3. Validation of BMP2 expression 72 h
following knockdown of KDM1A.
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